Ondine Cites Landmark Microbiome Study to Back Universal Nasal Photodisinfection

Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an update.

Ondine Biomedical has highlighted new evidence from a landmark Nature Communications study of the nasal microbiome that supports the company’s photodisinfection technology as an alternative to traditional antibiotic-based nasal decolonisation. The multicentre CARRIAGE study of about 1,180 healthy adults showed that Staphylococcus aureus colonisation exists as a stable, low-diversity microbial state and that so‑called intermittent carriers are actually persistent carriers with fluctuating bacterial loads, undermining the reliability of single-point screening and strengthening the case for universal, broad-spectrum decolonisation strategies such as Ondine’s Steriwave. The findings also indicate that conventional antibiotics can disrupt beneficial bacteria that naturally suppress S. aureus, whereas photodisinfection’s brief oxidative mechanism may help “reset” the nasal microbiome without promoting resistance, positioning the technology as a tool for hospitals and healthcare workers to curb hospital-acquired infections. Clinical evaluations presented at an international infection-control conference have reported up to a 70% reduction in surgical site infections and meaningful cost savings where universal photodisinfection protocols are used, and Ondine is already deploying the technology in Canadian and UK hospitals while targeting broader adoption across intensive care, dialysis, oncology and long-term care settings worldwide.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Spark’s Take on GB:OBI Stock

According to Spark, TipRanks’ AI Analyst, GB:OBI is a Underperform.

Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.

To see Spark’s full report on GB:OBI stock, click here.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Its flagship nasal photodisinfection system, marketed as Steriwave, is CE-marked in Europe and approved for nasal decolonisation in Canada, Australia, Mexico and several other countries, while products addressing chronic sinusitis, ventilator-associated pneumonia, burns and other indications are in various stages of development. In the United States, Ondine’s nasal technology has Qualified Infectious Disease Product and Fast Track designations from the FDA and is currently in Phase 3 clinical trials for regulatory approval.

Average Trading Volume: 189,025

Technical Sentiment Signal: Sell

Current Market Cap: £41.73M

Learn more about OBI stock on TipRanks’ Stock Analysis page.